Testosteronenantat Galenpharma
Testosterone enanthate 250 mg/ml solution for intramuscular injection – long-acting androgen replacement therapy for male hypogonadism
Quick facts about Testosteronenantat Galenpharma
Key takeaways about Testosteronenantat Galenpharma
- Only for confirmed male hypogonadism: Treatment must only be started after at least two separate morning blood tests confirm low testosterone, combined with clinical symptoms consistent with deficiency. It is not indicated for age-related testosterone decline in otherwise healthy older men.
- Long-acting depot injection: A single intramuscular dose of testosterone enanthate 250 mg/ml provides sustained testosterone release over 2–4 weeks, with peak serum levels at 24–72 hours and gradual decline thereafter. Serum levels may fluctuate between injections (“peak and trough” effect).
- Regular monitoring is mandatory: Blood tests for serum testosterone (trough), hematocrit, PSA, liver function, and lipid profile are required before, during the first year, and at least annually thereafter. Digital rectal examination and cardiovascular risk assessment are also essential.
- Not for women or children: Testosterone enanthate is absolutely contraindicated in women (risk of virilization and fetal harm) and in boys under 18 (risk of premature growth plate closure). Contact with the injection solution must be avoided by women of childbearing potential.
- Controlled substance with doping potential: Testosterone enanthate is a Schedule III controlled substance in the United States and is banned in competitive sports by WADA. Supraphysiological doses used illicitly for performance enhancement carry greatly increased cardiovascular, hepatic, and psychiatric risks.
What Is Testosteronenantat Galenpharma and What Is It Used For?
Testosteronenantat Galenpharma is a generic intramuscular preparation of testosterone enanthate 250 mg/ml, used as long-acting testosterone replacement therapy (TRT) in adult men with confirmed male hypogonadism. It restores serum testosterone to the normal physiological range, reversing symptoms such as decreased libido, erectile dysfunction, fatigue, depression, and loss of muscle and bone mass. It is administered as a deep intramuscular injection every 2–4 weeks.
Testosterone enanthate is a synthetic ester of the natural male sex hormone testosterone. The esterification with enanthoic acid (a seven-carbon fatty acid) produces a lipophilic compound that, when dissolved in an oily vehicle and injected intramuscularly, forms a depot at the injection site. The ester is slowly hydrolyzed by tissue esterases, releasing free testosterone into the bloodstream over a period of 2–4 weeks. This prolonged release profile allows dosing intervals of 2–4 weeks, making testosterone enanthate one of the most widely used formulations of testosterone replacement therapy worldwide.
Once released from the depot, testosterone exerts the same biological effects as endogenous testosterone produced by the testes. It binds to the intracellular androgen receptor (AR) in target tissues, translocates to the nucleus, and regulates the transcription of androgen-responsive genes. These genes control male sexual development and the maintenance of secondary sex characteristics, including the growth of the male reproductive organs, deepening of the voice, development of facial and body hair, and the regulation of muscle mass, bone density, fat distribution, libido, and erythropoiesis (red blood cell production).
Male hypogonadism is defined as a clinical syndrome resulting from the failure of the testes to produce adequate testosterone (androgen deficiency) and/or sperm (spermatogenic failure). According to the Endocrine Society Clinical Practice Guideline and the European Association of Urology (EAU), testosterone replacement therapy should only be initiated in men who have unequivocally low testosterone levels – confirmed by at least two morning blood samples taken several days apart – together with consistent clinical signs and symptoms of deficiency. Guidelines specifically caution against using TRT to treat age-related testosterone decline in otherwise healthy older men, as the balance of benefits and risks in this group remains uncertain.
The approved clinical indications for testosterone enanthate injection include:
- Primary hypogonadism: Testicular failure due to conditions such as Klinefelter syndrome (XXY), bilateral orchidectomy, cryptorchidism, testicular trauma, chemotherapy- or radiation-induced testicular damage, or congenital anorchia.
- Secondary (hypogonadotropic) hypogonadism: Hypothalamic or pituitary disorders causing deficient gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), or follicle-stimulating hormone (FSH) release, including pituitary tumors, Kallmann syndrome, pituitary surgery or radiation, and other pituitary diseases.
- Constitutional delay of puberty (short-term use) in selected adolescent boys under specialist endocrinological supervision – this is a specialist indication, outside routine adult TRT, and requires very careful monitoring of bone age.
The clinical symptoms of testosterone deficiency that may qualify a patient for TRT, in combination with biochemical confirmation, include:
- Sexual dysfunction: reduced libido, erectile dysfunction, reduced spontaneous morning erections, decreased orgasm intensity.
- Reduced fertility: oligospermia or azoospermia, though TRT itself further suppresses spermatogenesis and is not a fertility treatment.
- Physical changes: loss of muscle mass and strength (sarcopenia), increased central body fat, reduced bone mineral density and osteoporotic fractures, gynecomastia (breast enlargement), decreased body and facial hair.
- Psychological and cognitive symptoms: fatigue, low mood or depression, reduced motivation and concentration, decreased sense of wellbeing, sleep disturbance.
- Other effects: hot flushes, anemia, increased insulin resistance.
Testosterone enanthate is also one of the most commonly misused substances in bodybuilding and illicit performance enhancement. Supraphysiological doses (e.g., 500–1000 mg weekly) used for these purposes carry dramatically greater cardiovascular, hepatic, psychiatric, and reproductive risks than physiological replacement doses. Medical TRT aims to keep serum testosterone within the normal physiological range (typically 300–1000 ng/dL or 10.4–34.7 nmol/L). Use of testosterone outside of a medically supervised indication is not covered by this article.
Pharmacokinetic profile
After a single intramuscular injection of testosterone enanthate 250 mg, serum testosterone levels typically peak at approximately 24–72 hours, reaching supraphysiological concentrations (often above 1000 ng/dL), and then decline gradually over the following 2–3 weeks. By the end of a 3-week dosing interval, testosterone levels may fall back to or below the lower limit of the normal range in some patients, producing the characteristic “peak and trough” pattern that can cause fluctuations in symptoms, mood, energy, and libido. Individual pharmacokinetics vary considerably; some patients achieve stable levels on a 3- to 4-week schedule, while others require a shorter interval (e.g., every 1–2 weeks with lower per-injection doses) to maintain steady state.
What Should You Know Before Using Testosteronenantat Galenpharma?
Testosteronenantat Galenpharma is strictly for adult men with confirmed hypogonadism. It must not be used by women, children, or men with known or suspected prostate or breast cancer. Before starting therapy, testosterone deficiency must be confirmed by at least two separate morning blood tests combined with clinical symptoms. Important precautions apply in cardiovascular disease, polycythemia, severe liver, kidney, or heart failure, sleep apnea, and a history of blood clots.
Before starting testosterone enanthate, your doctor will perform a structured baseline evaluation to confirm the diagnosis, identify contraindications, and establish baseline values for ongoing monitoring. This evaluation typically includes a detailed medical and sexual history, examination of the testes and breasts, a digital rectal examination of the prostate, and laboratory tests (total testosterone, LH, FSH, prolactin, sex hormone–binding globulin, complete blood count, liver and kidney function, PSA, lipid profile, and fasting glucose or HbA1c). The decision to initiate TRT should be a shared decision between patient and physician, with a clear understanding of expected benefits, potential risks, and the commitment to long-term monitoring.
Contraindications
Testosteronenantat Galenpharma must not be used in the following situations:
- Known or suspected prostate cancer: Testosterone can stimulate the growth of androgen-responsive prostate cancer cells. All men require a PSA test and digital rectal examination before starting therapy, and abnormal findings must be evaluated by a urologist before TRT is started.
- Known or suspected breast cancer in men: Although male breast cancer is rare, it is typically hormone-sensitive, making androgen therapy an absolute contraindication.
- Hypersensitivity (allergy) to testosterone, arachis (peanut) oil, castor oil, benzyl benzoate, or any other excipient used in the formulation. Patients with known peanut or soya allergy should specifically avoid formulations containing arachis oil.
- Women and children: Testosterone enanthate is not indicated in women at any age and must not be used in boys under 18 years outside specific specialist indications, due to the risk of premature closure of bone growth plates and virilization. Pregnant or breastfeeding women must not be exposed to the product.
- Past or present liver tumors: Androgens have been associated with hepatic adenomas and, rarely, hepatocellular carcinoma.
Warnings and precautions
The following conditions require careful assessment before starting testosterone enanthate, and typically require closer monitoring or dose adjustment if treatment is initiated:
- Cardiovascular disease: Testosterone therapy has been associated with increased cardiovascular risk in some observational studies, particularly in older men with pre-existing cardiovascular disease. The U.S. FDA has required manufacturers to include cardiovascular risk information on testosterone product labels. The 2023 TRAVERSE trial (n=5,246), the largest randomized study of testosterone cardiovascular safety to date, did not demonstrate an increase in major adverse cardiovascular events with physiological replacement doses but did show small increases in atrial fibrillation, acute kidney injury, and pulmonary embolism.
- Polycythemia (erythrocytosis): Testosterone stimulates erythropoiesis, and injectable formulations tend to raise hematocrit more than transdermal gels due to higher peak levels. An elevated hematocrit increases blood viscosity and the risk of venous thromboembolism, stroke, and myocardial infarction. Hematocrit should be measured before starting, and if it exceeds 54%, testosterone must be held until values normalize.
- Benign prostatic hyperplasia (BPH) and lower urinary tract symptoms: Testosterone may exacerbate urinary obstruction. Severe symptomatic BPH is a relative contraindication.
- Sleep apnea: Testosterone can worsen obstructive sleep apnea, especially in obese men or those with predisposing anatomical factors. Patients with a history of snoring, witnessed apneas, or daytime sleepiness should be assessed before therapy.
- Severe heart, liver, or kidney disease: Testosterone can cause fluid and sodium retention (edema), which may decompensate heart failure or worsen chronic kidney or liver disease.
- Thrombophilia or previous venous thromboembolism: Testosterone can increase the risk of deep vein thrombosis and pulmonary embolism, particularly in individuals with inherited thrombophilia (e.g., Factor V Leiden).
- Epilepsy and migraine: These conditions may be worsened by fluid retention during testosterone therapy.
- Diabetes mellitus: Testosterone often improves insulin sensitivity, so patients on insulin or oral antidiabetic drugs may require dose reduction to avoid hypoglycemia.
- Bone metastases from any cancer: Risk of hypercalcemia (high calcium) and pathological fractures.
- Elderly patients: Limited data on long-term safety above age 65; closer prostate and cardiovascular monitoring is advised. Routine TRT for age-related testosterone decline is not recommended.
Seek urgent medical attention if you experience any of the following: painful swelling in a leg, sudden change in skin color (pale, red, or blue) in a limb, sudden shortness of breath, unexplained cough with or without blood, sudden chest pain, severe headache or dizziness, slurred speech, one-sided weakness, severe abdominal pain, or sudden vision loss. These may indicate deep vein thrombosis, pulmonary embolism, stroke, or myocardial infarction – all of which have been reported with testosterone therapy.
Pulmonary oil microembolism (POME) and anaphylactic reactions
Because testosterone enanthate is dissolved in an oily vehicle for intramuscular injection, there is a small risk of pulmonary oil microembolism (POME) if the oily solution inadvertently enters the bloodstream during or shortly after injection. POME can cause cough, urge to cough, dyspnea (shortness of breath), chest tightness, throat tightening, chest pain, dizziness, syncope, and, in very rare cases, cardiopulmonary arrest. Symptoms typically occur during or within minutes of injection and usually resolve spontaneously within a few minutes. Although reported more frequently with testosterone undecanoate, POME can occur with any oily intramuscular testosterone formulation, including testosterone enanthate.
Anaphylaxis has also been reported, albeit rarely, after testosterone injection. For these reasons, injections should be administered by a trained healthcare professional in a setting where the patient can be observed for 30 minutes after administration and emergency treatment is available.
Pregnancy, breastfeeding, and partners of childbearing potential
Testosterone enanthate is absolutely contraindicated in women, including pregnant and breastfeeding women. Testosterone crosses the placenta and can cause virilization of a female fetus, producing abnormal development of external genitalia. Pregnant women must not handle the injection solution, and direct contact with the unwashed injection site should be avoided for at least a few hours after injection. If accidental contact occurs, the exposed area should be washed immediately with soap and water.
Although testosterone transfer via sexual contact from a male patient to a partner is less of a concern than with gels, any visible injection solution on the skin should be wiped away and the area washed before intimate contact. Men planning to father children should discuss alternative strategies with their doctor (see Effects on fertility below) before starting TRT.
Effects on fertility
Testosterone replacement therapy suppresses endogenous gonadotropin release (LH and FSH) via negative feedback on the hypothalamic-pituitary axis, which in turn suppresses intratesticular testosterone production and spermatogenesis. Most men on TRT experience a significant reduction in sperm count, often to zero (azoospermia), with resultant infertility. Fertility usually, but not always, recovers within 6–24 months of discontinuing therapy.
Men who wish to preserve fertility should discuss alternatives before starting testosterone. Options include clomiphene citrate, human chorionic gonadotropin (hCG) alone or in combination with recombinant FSH, and aromatase inhibitors. These alternatives work by stimulating the body's own testosterone production while maintaining or even enhancing spermatogenesis. Semen cryopreservation may also be considered.
Testosterone and its esters are classified as prohibited substances by the World Anti-Doping Agency (WADA) and are banned in virtually all competitive sports, both in and out of competition. Athletes using medically prescribed testosterone must apply for a Therapeutic Use Exemption (TUE) before competing; without this, use will result in a positive doping test. Testosterone is also a Schedule III controlled substance in the United States.
How Does Testosteronenantat Galenpharma Interact with Other Drugs?
Testosterone enanthate interacts with several medications including oral anticoagulants (warfarin), insulin and oral antidiabetics, corticosteroids, and some CYP3A4 inhibitors and inducers. These interactions may require dose adjustments or closer monitoring. Always provide your doctor with a complete list of all prescription medications, over-the-counter products, and herbal supplements before starting testosterone therapy.
Testosterone is primarily metabolized in the liver, predominantly by the CYP3A4 isoenzyme, with subsequent conversion to dihydrotestosterone (via 5α-reductase) and estradiol (via aromatase). Because of this metabolic profile, CYP3A4 inhibitors and inducers may modestly affect testosterone exposure, although the clinical relevance is usually limited at replacement doses. More clinically important interactions relate to testosterone's pharmacodynamic effects, particularly on coagulation, glucose metabolism, and fluid balance.
Major interactions
| Interacting Drug | Effect | Clinical Significance | Action Required |
|---|---|---|---|
| Oral anticoagulants (warfarin, acenocoumarol) | Testosterone enhances anticoagulant effect, increasing bleeding risk | High | More frequent INR monitoring; anticoagulant dose may need reduction after starting or adjusting testosterone |
| Insulin and oral antidiabetics | Testosterone improves insulin sensitivity, lowering blood glucose | High | Monitor blood glucose frequently; reduce insulin or antidiabetic dose if hypoglycemia occurs |
| Corticosteroids (prednisolone, dexamethasone) | Both promote sodium and fluid retention; combined use increases edema risk | Moderate to High | Use with caution in heart, liver, or kidney disease; monitor for edema and blood pressure |
| Cyclosporine | Testosterone may increase cyclosporine levels and nephrotoxicity risk | Moderate | Monitor cyclosporine levels and renal function closely |
| Levothyroxine (thyroid hormone) | Testosterone may lower thyroxine-binding globulin, altering free T4 | Low to Moderate | Re-check TSH after dose changes; usually no dose adjustment needed |
| ACTH and licorice | Additive fluid retention and potential potassium loss | Moderate | Avoid concurrent use where possible; monitor electrolytes |
Minor interactions
Other medications that may interact with testosterone enanthate include:
- Oxyphenbutazone: May increase testosterone plasma levels when used concurrently.
- CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, erythromycin, clarithromycin, grapefruit juice): May theoretically increase testosterone exposure; the effect is typically modest at replacement doses but should be considered if testosterone levels become supraphysiological.
- CYP3A4 inducers (rifampicin, phenytoin, phenobarbital, carbamazepine, St John's wort): May increase testosterone metabolism, potentially lowering serum levels and reducing treatment effectiveness.
- 5α-reductase inhibitors (finasteride, dutasteride): Reduce conversion of testosterone to dihydrotestosterone (DHT); not a direct pharmacokinetic interaction with testosterone itself but may alter prostate and hair effects.
- Aromatase inhibitors (anastrozole, letrozole): Reduce conversion of testosterone to estradiol; occasionally used off-label to manage gynecomastia or elevated estradiol in men on TRT, under specialist supervision.
Always provide your physician and pharmacist with a complete list of every medication, vitamin, and herbal supplement you take. Supplements such as Tribulus terrestris, DHEA, saw palmetto, and over-the-counter “test boosters” are of particular concern because their content and safety are often poorly characterized.
What Is the Correct Dosage of Testosteronenantat Galenpharma?
The typical dose of testosterone enanthate 250 mg/ml for adult male hypogonadism is 250 mg by deep intramuscular injection every 2–3 weeks, adjusted according to serum testosterone levels and clinical response. Dose intervals may range from every 1 week (in patients with rapid metabolism) to every 4 weeks, and daily doses of 25–75 mg (as equivalent total) per week are typical. The goal is to maintain trough testosterone within the normal physiological range (300–1000 ng/dL or 10.4–34.7 nmol/L).
Testosterone dosing is highly individualized. The goal of replacement therapy is to maintain serum testosterone concentrations within the physiological range throughout the dosing interval. Because injectable testosterone enanthate produces a peak at 24–72 hours after injection followed by a gradual decline, most guidelines recommend measuring testosterone just before the next scheduled injection (a “trough” level) and aiming for mid-to-low normal values at that time point. Peak levels measured 2–3 days after injection may be supraphysiological, which is expected with this formulation.
Adults – standard regimens
Initial dose
250 mg (1 ml) deep intramuscular injection every 2–3 weeks. Some clinicians prefer to start with 125 mg every 1–2 weeks to achieve smoother serum levels, particularly in patients with smaller body size or a history of mood instability.
Route: Deep intramuscular injection into the upper outer quadrant of the gluteal muscle (buttock). The vastus lateralis (lateral thigh) is an acceptable alternative when self-administration is supervised by a trained professional.
Injection technique: The vial should be warmed to body temperature and inspected for particulate matter. A 21G (green) needle is typically used for adults; a longer needle (e.g., 38 mm) may be required for obese patients to ensure intramuscular rather than subcutaneous deposition. Aspirate before injection to exclude intravascular placement. Inject slowly over 1–2 minutes. Observe the patient for 30 minutes after injection for signs of POME or hypersensitivity.
Maintenance dose
Range: 100–300 mg intramuscularly every 2–4 weeks, adjusted according to clinical response and trough serum testosterone levels.
Adjustment: If the trough testosterone is below the normal range or symptoms reappear before the next injection, the dose may be increased or, preferably, the interval shortened (e.g., from every 3 weeks to every 2 weeks). Conversely, if hematocrit, estradiol, or PSA rise excessively, the dose may be reduced or the interval lengthened.
| Regimen | Dose per Injection | Interval | Approximate Weekly Equivalent |
|---|---|---|---|
| Standard (typical starting) | 250 mg (1 ml) | Every 3 weeks | ~83 mg/week |
| Intensified standard | 250 mg (1 ml) | Every 2 weeks | ~125 mg/week |
| Smoother profile (split) | 125 mg (0.5 ml) | Every week | 125 mg/week |
| Lower dose (elderly or low body weight) | 125 mg (0.5 ml) | Every 2 weeks | ~62 mg/week |
| Extended (stable low maintenance) | 250 mg (1 ml) | Every 4 weeks | ~62 mg/week |
How testosterone enanthate is injected
Testosterone enanthate 250 mg/ml is an oily intramuscular solution and must never be given intravenously. Proper injection technique is essential to ensure correct depot formation, avoid pulmonary oil microembolism, and minimize injection site discomfort:
- Inspect the ampoule or vial: the solution should be clear, pale yellow, and free of particulate matter. Do not use if it looks cloudy or discolored.
- Warm the solution to body temperature between the palms; cold oil is more viscous and painful to inject.
- Draw up the prescribed dose using a sterile drawing-up needle, then change to a clean intramuscular needle (typically 21G, 38–50 mm length depending on patient size).
- Select the injection site – usually the upper outer quadrant of the gluteus medius (dorsogluteal) or, alternatively, the ventrogluteal or vastus lateralis site. The deltoid is generally not recommended because of the large injection volume.
- Clean the skin with an alcohol swab and allow it to dry.
- Insert the needle rapidly at 90° to the skin, to its full length.
- Aspirate for at least 5 seconds to confirm the needle is not in a blood vessel. If blood appears, withdraw the needle, discard, and use a fresh needle at a different site.
- Inject slowly over 1–2 minutes.
- Withdraw the needle, apply gentle pressure with sterile gauze, and, if possible, massage the site to aid dispersion.
- Observe the patient for at least 30 minutes after injection for cough, dyspnea, chest pain, urticaria, or hypotension.
Testosterone enanthate is dissolved in an oily vehicle and must only be given by deep intramuscular injection. Accidental intravenous administration can cause severe pulmonary oil microembolism, resulting in cough, dyspnea, chest pain, and, rarely, cardiopulmonary collapse. Always aspirate before injecting and inject slowly.
Adjustment based on laboratory results
Your physician will use a combination of clinical symptoms and laboratory results to adjust the dose:
- Trough testosterone below 300 ng/dL (10.4 nmol/L) with persistent symptoms: increase dose by 25–50 mg per injection or shorten the interval by 1 week.
- Trough testosterone above 700 ng/dL or peak levels above 1500 ng/dL with symptoms such as aggression or acne: reduce dose or lengthen the interval.
- Hematocrit > 54%: hold testosterone, consider therapeutic phlebotomy, and restart at a lower dose or longer interval when hematocrit normalizes.
- PSA rise > 1.4 ng/mL in 12 months or absolute PSA > 4 ng/mL: refer for urological evaluation.
Children and adolescents
Testosterone enanthate is not recommended in boys under 18 for routine use. In highly selected adolescents with delayed puberty or specific endocrine disorders, short-term low-dose testosterone may be used under specialist supervision, with careful monitoring of bone age and growth. Long-term or high-dose use can cause premature closure of the epiphyseal growth plates and reduced final adult height, as well as inappropriate virilization.
Elderly
Routine testosterone replacement for age-related testosterone decline in otherwise healthy older men is not recommended by the Endocrine Society, EAU, or AUA guidelines. Where TRT is prescribed for confirmed hypogonadism in older men, lower starting doses, more frequent prostate and hematocrit monitoring, and careful cardiovascular risk assessment are recommended. Intramuscular depot injections may be less preferable than transdermal formulations in frail elderly patients because of the greater fluctuations in serum levels and higher risk of polycythemia.
Missed dose
If an injection is missed, administer it as soon as possible and then adjust the schedule so that the next injection is given at the usual interval from the delayed dose (rather than the originally scheduled date). Do not inject a double dose to compensate. If the delay is significant (more than 1 week beyond the scheduled date), inform your physician, as temporary symptom recurrence is likely.
Overdose
Acute overdose with testosterone enanthate is very rare given the intramuscular route and fixed ampoule sizes. Chronic excessive dosing produces signs of androgen excess, including:
- Polycythemia (raised hematocrit and hemoglobin)
- Severe acne and oily skin
- Hypertension and fluid retention
- Priapism (prolonged and painful erection)
- Irritability, aggression, insomnia, and mood instability
- Gynecomastia from increased aromatization to estradiol
- Hepatic dysfunction (rare with injectable esters, more common with oral 17α-alkylated androgens)
If overdose is suspected, injections should be withheld and the patient monitored until levels normalize. Accidental injection in a woman or child requires urgent medical evaluation.
What Are the Side Effects of Testosteronenantat Galenpharma?
Common side effects of testosterone enanthate include increased red blood cell count (polycythemia), acne, mood changes, fluid retention, elevated blood pressure, injection site pain, and gynecomastia. Serious but less common adverse effects include pulmonary oil microembolism (POME), anaphylactic reactions, venous thromboembolism, cardiovascular events, and liver dysfunction. Regular laboratory and clinical monitoring is essential to detect adverse effects early.
Like all medications, testosterone enanthate may cause adverse effects. Most side effects are dose-dependent and related to achieving supraphysiological testosterone levels, particularly in the days immediately after injection. They often resolve or improve after dose adjustment. Side effect frequencies are based on data from spontaneous post-marketing reports and clinical trials, and are classified using the standard MedDRA frequency categories.
Very Common
- Increased red blood cell count, hemoglobin, and hematocrit (polycythemia/erythrocytosis)
- Injection site pain, tenderness, or irritation
Common
- Acne and oily skin (seborrhea)
- Mood changes (irritability, aggression, insomnia, mood swings)
- Increased libido
- Weight gain
- Fluid retention (edema) and peripheral edema
- Hypertension (elevated blood pressure)
- Headache
- Gynecomastia (breast tenderness or enlargement)
- Elevated estradiol levels
- Elevated prostate-specific antigen (PSA)
- Abnormal lipid profile (elevated LDL, reduced HDL)
- Depression, nervousness
Uncommon
- Injection site reactions (bruising, hemorrhage, inflammation, nodule, induration)
- Prostate enlargement, worsening lower urinary tract symptoms, urinary urgency
- Hair loss (androgenic alopecia)
- Hirsutism in close contacts from accidental transfer
- Abnormal liver function tests (mildly elevated ALT/AST)
- Hot flushes
- Priapism (prolonged and painful erection)
- Testicular atrophy and oligospermia/azoospermia
- Hypercholesterolemia, dyslipidemia
- Palpitations
Rare
- Pulmonary oil microembolism (POME) – cough, dyspnea, chest pain, throat tightening during or immediately after injection
- Hypersensitivity or anaphylactic reactions
- Venous thromboembolism (deep vein thrombosis, pulmonary embolism)
- Myocardial infarction, stroke
- Hepatic adenoma (benign liver tumor)
- Obstructive sleep apnea (new or worsening)
- Jaundice (cholestatic)
Very Rare & Frequency Not Known
- Hepatocellular carcinoma (very rare, reported primarily with 17α-alkylated oral androgens)
- Prostate cancer (frequency not known; testosterone does not initiate prostate cancer but may accelerate pre-existing occult disease)
- Severe hypercalcemia (in patients with bone metastases)
- Electrolyte disturbance: sodium, chloride, potassium, and calcium retention
- Sudden cardiac death (rare post-marketing reports, mostly in patients with pre-existing cardiac disease or supraphysiological dosing)
- Anxiety and psychiatric disturbance (including hostility and mania at high doses)
The single most common and clinically important laboratory abnormality during testosterone enanthate therapy is an increase in red blood cell count and hematocrit. Injectable depot formulations with high peak concentrations tend to cause more erythrocytosis than transdermal gels. A hematocrit above 54% significantly increases blood viscosity and the risk of thrombotic events (stroke, heart attack, deep vein thrombosis). Guidelines therefore recommend checking hematocrit before therapy, at 3 and 6 months in the first year, and at least annually thereafter. If hematocrit exceeds 54%, testosterone should be held, and therapeutic phlebotomy may be considered.
If you experience any side effect, talk to your doctor, nurse, or pharmacist. This includes any side effects not listed above. You or your healthcare professional can also report suspected adverse reactions directly to your national medicines regulator (for example, the MHRA Yellow Card scheme in the UK, FDA MedWatch in the US, or the EMA EudraVigilance system in the EU). Reporting helps identify new safety information about testosterone products.
How Should You Store Testosteronenantat Galenpharma?
Store testosterone enanthate 250 mg/ml ampoules or vials at room temperature below 25°C (77°F), protected from light. Do not refrigerate or freeze. Keep the product in its original outer carton until use. Keep out of the sight and reach of children. Do not use after the expiry date printed on the packaging. Dispose of unused medication and used needles through your pharmacy or an authorised medical waste service.
Correct storage preserves the chemical stability of testosterone enanthate in its oily vehicle and helps prevent accidental exposure of others. Follow these guidelines:
- Temperature: Store below 25°C (77°F). Avoid exposure to temperatures above 30°C. Do not refrigerate: refrigeration can cause the oily solution to become viscous and may promote crystallization.
- Light: Keep ampoules or vials in their original outer packaging to protect from light. Prolonged light exposure can degrade testosterone esters.
- Moisture: Do not store in bathrooms or other humid environments.
- Keep out of reach of children: Accidental injection, oral ingestion, or skin contact in children can cause serious adverse effects including virilization, premature puberty, and hepatic injury.
- Check expiry date: Do not use after the expiry date (EXP) printed on the carton and ampoule. Once an ampoule is opened, the contents should be used immediately; any remaining solution should be discarded.
- Safe disposal: Do not dispose of testosterone through household waste or wastewater. Return unused or expired ampoules and used syringes/needles to your pharmacy or an authorised sharps disposal service. This protects the environment and prevents misuse.
What Does Testosteronenantat Galenpharma Contain?
Each ml of Testosteronenantat Galenpharma 250 mg/ml solution for injection contains 250 mg of testosterone enanthate as the active substance, dissolved in an oily vehicle. The excipients typically include a fatty oil (such as castor oil or arachis oil) and benzyl benzoate, which act as solvents to keep the testosterone ester in solution for injection.
Active ingredient
The active substance is testosterone enanthate, the enanthic (heptanoic) acid ester of testosterone. Each 1 ml of solution contains 250 mg of testosterone enanthate, which corresponds to approximately 180 mg of testosterone base after ester hydrolysis. Testosterone enanthate has a molecular formula of C26H40O3 and a molecular weight of 400.59 g/mol. Its pharmacological activity is mediated entirely by the testosterone released after hydrolysis by tissue esterases at the injection site.
Excipients (inactive ingredients)
As with other testosterone ester injections, Testosteronenantat Galenpharma is formulated as an oily solution. Typical excipients for this class of product include:
- Fatty oil vehicle: A pharmaceutical-grade vegetable oil such as castor oil or arachis (peanut) oil, which dissolves the lipophilic testosterone ester and forms the depot at the intramuscular injection site.
- Benzyl benzoate: A co-solvent that increases the solubility of testosterone enanthate in the oil base.
- Benzyl alcohol: Occasionally included as a preservative in multidose presentations; may rarely cause hypersensitivity.
If the formulation contains arachis (peanut) oil, it must not be used in patients with a known allergy to peanuts or soya, as cross-reactivity is possible and severe allergic reactions have been reported. Always check the specific package leaflet for the exact excipient composition of your ampoule before first use.
Packaging
Testosteronenantat Galenpharma 250 mg/ml is typically supplied as clear glass ampoules of 1 ml, packed in cartons containing one or more ampoules. Not all pack sizes may be marketed in every country. The solution is a clear, pale yellow to yellow, oily liquid.
What Monitoring Is Required During Treatment?
Regular monitoring during testosterone enanthate therapy includes serum testosterone (trough level), complete blood count (especially hematocrit), PSA, liver function tests, lipid profile, and blood pressure. Digital rectal examination of the prostate should be performed at baseline and at least annually thereafter. Additional assessments (bone densitometry, sleep apnea screening) may be required based on clinical risk factors.
Ongoing surveillance is a core component of safe and effective testosterone replacement therapy. Both the Endocrine Society (2018) and the European Association of Urology recommend a structured monitoring schedule to optimize efficacy, minimize cardiovascular and prostate-related risks, and adjust dosing over time. Monitoring intervals vary between guidelines but generally follow the pattern shown below.
Recommended monitoring schedule
| Test | Baseline | First Year | Ongoing |
|---|---|---|---|
| Serum testosterone (trough) | Two morning samples before starting | At 3 and 6 months; just before next injection | Every 6–12 months |
| Hematocrit / Full blood count | Before starting | At 3, 6, and 12 months | Every 6–12 months |
| PSA (prostate-specific antigen) | Before starting | At 3–6 months and 12 months | Annually (more often if >40 years) |
| Lipid profile | Before starting | At 6–12 months | Annually |
| Liver function tests (ALT, AST, ALP, bilirubin) | Before starting | At 3–6 months | As clinically indicated |
| Blood pressure | Before starting | At every clinic visit | At every clinic visit |
| Digital rectal examination (DRE) | Before starting | At 3–12 months | Annually (or biannually if >40 years) |
| Bone mineral density (DEXA) | If baseline osteoporosis or high fracture risk | – | Every 1–2 years if osteoporosis |
| Sleep apnea screening | Ask about symptoms | Reassess if symptoms develop | Reassess if symptoms develop |
If the trough testosterone is outside the target range, the dose or interval is adjusted (see Dosage section). If hematocrit exceeds 54%, testosterone is held until values normalize, and therapeutic phlebotomy may be considered. A rise in PSA greater than 1.4 ng/mL over 12 months, an absolute PSA above 4 ng/mL, or any abnormal finding on digital rectal examination warrants specialist urological evaluation to exclude prostate cancer before treatment continues.
For short-acting testosterone esters such as testosterone enanthate, the most informative sample for dose titration is a trough level taken just before the next scheduled injection. Mid-interval and peak samples (24–72 hours after injection) are expected to be higher and should not be used to guide dose reduction unless clearly supraphysiological and associated with symptoms. Aim to achieve a trough in the mid-to-low physiological range (approximately 300–500 ng/dL or 10–17 nmol/L) for most patients.
Frequently Asked Questions About Testosteronenantat Galenpharma
Medical References and Sources
This article is based on current medical research and international guidelines. All claims are supported by scientific evidence from peer-reviewed sources.
- Bhasin S, Brito JP, Cunningham GR, et al. (2018). “Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.” Journal of Clinical Endocrinology & Metabolism Comprehensive clinical practice guideline for testosterone therapy. Evidence level: 1A
- European Association of Urology (EAU) (2024). “Guidelines on Male Hypogonadism.” EAU Guidelines European guidelines for diagnosis and treatment of male hypogonadism.
- Mulhall JP, Trost LW, Brannigan RE, et al. (2018). “Evaluation and Management of Testosterone Deficiency: AUA Guideline.” Journal of Urology. 200(2):423–432. AUA Guidelines American guidelines for evaluation and management of testosterone deficiency.
- European Medicines Agency (EMA). “Testosterone-containing medicines – Summary of Product Characteristics.” EMA Official European regulatory information on testosterone products.
- U.S. Food and Drug Administration (FDA) (2015, updated 2018). “FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging.” FDA Safety Communication FDA safety communication regarding cardiovascular risks and appropriate use of testosterone.
- Lincoff AM, Bhasin S, Flevaris P, et al. (2023). “Cardiovascular Safety of Testosterone-Replacement Therapy.” New England Journal of Medicine. 389(2):107–117. NEJM TRAVERSE trial – largest randomized trial of testosterone cardiovascular safety (n=5,246).
- Corona G, Goulis DG, Huhtaniemi I, et al. (2020). “European Academy of Andrology (EAA) guidelines on investigation, treatment, and monitoring of functional hypogonadism in males.” Andrology. 8(5):970–987. Andrology European andrology guidelines for functional hypogonadism management.
- Snyder PJ, Bhasin S, Cunningham GR, et al. (2016). “Effects of Testosterone Treatment in Older Men.” New England Journal of Medicine. 374(7):611–624. NEJM Landmark Testosterone Trials (TTrials) investigating effects of testosterone in older men.
- British National Formulary (BNF). “Testosterone enanthate – drug monograph.” BNF (NICE) UK national prescribing reference for testosterone enanthate.
- Shankara-Narayana N, Yu C, Savkovic S, et al. (2020). “Rate and Extent of Recovery from Reproductive and Cardiac Dysfunction Due to Androgen Abuse in Men.” Journal of Clinical Endocrinology & Metabolism. 105(6):e1979–e1989. JCEM Evidence on long-term reproductive and cardiac effects of androgen use.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Evidence level 1A represents the highest quality of evidence, based on systematic reviews of randomized controlled trials.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in endocrinology, clinical pharmacology, urology, and internal medicine.